Capricor Therapeutics
CAPR
19 hedge funds and large institutions have $2.29M invested in Capricor Therapeutics in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.12% less ownership
Funds ownership: 0.83% → 0.71% (-0.12%)
30% less capital invested
Capital invested by funds: $3.25M → $2.29M (-$964K)
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$19.6K |
| 2 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$8.93K |
| 3 |
BlackRock
New York
|
+$2.14K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
+$1.19K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$989 |
Top Sellers
| 1 |
Brown Advisory
Baltimore,
Maryland
|
-$254K |
| 2 |
VF
Virtu Financial
New York
|
-$54.4K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$16K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.35K |
| 5 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
-$774 |
CAPR Hedge Fund Activity: Q3 2018 in Review
19 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q3 2018, worth a combined $2.29M — down 30% from $3.25M a quarter earlier.
Fund positioning in CAPR was balanced in Q3 2018: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 5 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $19.6K. The largest seller was Brown Advisory, cutting an estimated $254K.
- 19 institutional investors held Capricor Therapeutics (CAPR) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $2.29M of Capricor Therapeutics stock for Q3 2018, down 30% quarter-over-quarter.
- 1 fund opened new Capricor Therapeutics positions in Q3 2018 and 1 closed out, a net change of 0 holders.
- The largest Capricor Therapeutics buyer in Q3 2018 was Citadel Advisors, an estimated $19.6K added.
- The largest Capricor Therapeutics seller in Q3 2018 was Brown Advisory, an estimated $254K sold.
Based on aggregated 13F filings for Q3 2018.